Business Context and Reporting Period
Company: Black Hawk Acquisition Corporation (BKHA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 26, 2025
Event: Entry into a Material Definitive Agreement (Business Combination Agreement) with Vesicor Therapeutics, Inc., a development-stage biopharmaceutical company focused on p53-based cancer therapeutics delivered via microvesicles.
Transaction Structure: The Company will domesticate from the Cayman Islands to Delaware ("Domestication") and merge with Vesicor via a wholly-owned subsidiary ("Merger"). Vesicor will become the surviving company and a wholly-owned subsidiary of the public company ("PubCo").
Key Financial Metrics and Transaction Terms
Equity Value: $70,000,000 (Aggregate Merger Consideration basis).
Consideration Ratio: To be determined by dividing the Equity Value by the Redemption Price of Parent Class A Ordinary Shares, then dividing that result by the Aggregate Fully Diluted Company Shares.
PIPE Investment (PPM Investment): Vesicor is required to procure a minimum of $10,000,000 in transaction financing (cash equity, equity-linked instruments, debt, or working capital investment) as a condition to closing.
Break-up Fee: $1,000,000 payable by the breaching party to the non-breaching party upon termination under specific circumstances.
Financial Statements: The filing does not provide current revenue, profit, cash flow, or debt metrics for either entity. Vesicor is described as a development-stage company.
Material Changes and Conditions to Closing
- Corporate Status Change: Black Hawk Acquisition Corporation will cease to exist as a Cayman Islands entity and become a Delaware corporation.
- Share Conversion: Parent Class A Ordinary Shares convert 1:1 to PubCo Common Stock. Parent Units separate into Common Stock and Rights.
- Key Closing Conditions:
- SEC effectiveness of the Form S-4 Registration Statement.
- Approval by Black Hawk and Vesicor shareholders.
- Procurement of the $10 million PPM Investment by Vesicor.
- Receipt of a fairness opinion from an investment bank.
- Delivery of audited financial statements by Vesicor by June 10, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company expects to file the Registration Statement promptly. Closing is expected following the fulfillment of conditions. The post-transaction executive team will include Dr. Luo Feng (CEO), Michael Bowen (CFO), and Warren Hosseinion Jr. (COO).
Governance: The PubCo Board will consist of five members: one designated by Black Hawk, one by Vesicor, and three independent directors.
Lock-Up Agreements:
- PubCo shareholders: 6-month lock-up period.
- Vesicor Warrant holders: 12-month lock-up period.
Risks and Contingencies:
- Termination Risks: The agreement may be terminated if shareholder approval is not obtained, if the PPM Investment is not procured, or if Vesicor fails to deliver financial statements by June 10, 2025.
- Forward-Looking Statements: Actual results may differ due to regulatory delays, failure to obtain approvals, or inability to list on Nasdaq.
- Development Stage: Vesicor is a development-stage company, implying no current commercial revenue.
Investor Verification Checklist
- Verify the final Redemption Price to calculate the exact Consideration Ratio and share issuance.
- Confirm the successful procurement of the $10 million PPM Investment by Vesicor.
- Monitor the filing and effectiveness of the Form S-4 Registration Statement.
- Review the upcoming proxy statement/prospectus for detailed risk factors and financial data.
- Check for the delivery of Vesicor's audited financial statements by the June 10, 2025 deadline.
- Confirm the composition of the new Board of Directors and executive team.